Stock Financial Ratios, Dividends, Split History

HRI / Herc Holdings Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price58.57
Volume263,300.00
Market Cap ($M)1,857.57
Enterprise Value ($M)3,975.87
Book Value ($M)500.30
Book Value / Share17.60
Price / Book3.64
NCAV ($M)-2,637.40
NCAV / Share-92.79
Price / NCAV-0.63
Share Statistics
Common Shares Outstanding 28,399,244
Common Stock Shares Outstanding 28,300,000
Preferred Stock Shares Outstanding 0
Weighted Average Number Of Shares Outstanding Basic 28,300,000
Weighted Average Number Of Diluted Shares Outstanding 28,600,000
Scoring Models
Piotroski F-Score6.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.06
Return on Assets (ROA)0.05
Return on Equity (ROE)0.50
Balance Sheet (mrq) ($M)
Assets3,573.90
Liabilities3,073.60
Quick Ratio1.00
Current Ratio1.05
Income Statement (mra) ($M)
Sales Revenue Goods Net52,300,000.00
Sales Revenue Revenue Earning Equipment Net190,800,000.00
Sales Revenue Partsand Supplies0.00
Sales Revenue Net1,754,500,000.00
Sales Revenue Services Net12,400,000.00
Sales Revenue Revenue Earning Equipment Gross0.00
Sales Revenue New Equipment0.00
Net Income160.30
Earnings Per Share Basic5.66
Earnings Per Share Diluted5.60
Cash Flow Statement (mra) ($M)
Cash From Operations341.70
Cash from Investing-403.00
Cash from Financing-403.00
Identifiers and Descriptors
CUSIP42805T105
Central Index Key (CIK)1364479
Related CUSIPS
42704L904 42704L954 42704L104

Split History

Stock splits are used by Herc Holdings Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

3h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Old Dominion (ODFL) Hits a 52-Week High, Can the Run Continue?

2018-06-11 zacks
Have you been paying attention to shares of Old Dominion Freight Line (ODFL - Free Report) ? Shares have been on the move with the stock up 10.7% over the past month. ODFL hit a new 52-week high of $161.04 in the previous session. Old Dominion Freight Line has gained 22.1% since the start of the year compared to the 1.1% move for the Transportation sector and the 9.4% year-to-date return for its peer group. (25-0)

Cramer's lightning round: Auto pain shouldn't hurt Illinois Tool Works

2018-06-06 cnbc
Illinois Tool Works: "The issue here is Scott Santi, who is absolutely terrific, has a big auto business. And even though they said repeatedly that the auto business is getting better, Scott has been under the gun here. I want him to stick by his knitting and just keep doing what he's doing. It's a very similar situation to 3M, another high-quality company that's been hurt by autos. They've got to stick by what they believe in and then the stocks will go higher over time. (70-0)

Why Hertz Is Quietly Tumbling

2018-06-04 seekingalpha
The company has unreliable earnings due to frequent non-recurring adjustables, resulting in GAAP figures that obfuscate the underlying economics of the business. (44-0)

Is Herc Holdings (HRI) Stock a Solid Choice Right Now?

2018-05-29 zacks
One stock that might be an intriguing choice for investors right now is Herc Holdings Inc. (HRI - Free Report) . This is because this security in the Transportation - Equipment and Leasing space is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective. (15-0)

Can Higher Networking Revenues Aid Ciena (CIEN) Q2 Earnings?

2018-05-28 zacks
Ciena Corporation (CIEN - Free Report) is scheduled to report second-quarter fiscal 2018 financial results (ending Apr 28, 2018) before the opening bell on May 31. The company is likely to report higher consolidated revenues led by healthy growth dynamics. Whether this could result into an earnings beat remains to be seen. Factors to Consider During the quarter, Ciena’s GeoMesh solution was selected by Sweden-based Eastern Light to help meet the region’s fast-growing demand for long-haul dark fiber. (27-0)

CUSIP: 42805T105